Solutions for COVID-19 vaccine safety and immunogenicity evaluation

Fig 3. Immobilized Biotinylated SARS-CoV-2 S protein RBD, His,Avitag (Cat. No. SPD-C82E9) at 1 μg/mL (100 μL/well) on Streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Monoclonal Anti-SARS-CoV-S protein RBD Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL

Pfizer employed ACROBiosystems' featured biotinylated S protein RBD in the RBD-binding IgG assay during the phase 1/2 research. The interim report showed that the biotinylated S protein RBD from ACROBiosystems （Cat.No. SPD-C82E9）was bound to streptavidin-coated Luminex microspheres.^[1]

Fig 7. Inhibition of Human ACE2: SARS-CoV-2 Spike RBD (HRP) binding by Anti-SARS-CoV-2 Neutralizing Antibody measured by competitive ELISA Assay.
Serial dilutions of Anti-SARS-CoV-2 Neutralizing Antibody (Cat. No. TAS022-C02) (1:2 serial dilutions, from 1.25 μg/mL to 0.0012 μg/mL) was added into Human ACE2: SARS-CoV-2 Spike RBD (HRP) binding reactions. The assay was performed according to the above described protocol. Background was subtracted from data points prior to log transformation and curve fitting. A representative result showed that the IC50 was calculated to be 0.06 μg/mL

Fig 8. This assay kit employs a standard sandwich-ELISA format, providing a rapid detection of SARS-CoV-2 Spike protein. The kit consists of pre-coated Anti-SARS-CoV-2 Spike Protein Antibody Microplate, SARS-CoV-2 Spike protein as Control, biotin-Anti-SARS-CoV-2 Spike protein antibody and HRP-Streptavidin. Detection is performed using HRP-Streptavidin with sensitivity of 200 pg/mL.

Fig.4 cross-validation data for antibody subtype detection